Hexima (ASX:HXL) Additional Paid-In Capital : A$0.00 Mil(As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hexima Additional Paid-In Capital?

Hexima Additional Paid-In Capital Historical Data

The historical data trend for Hexima's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima Additional Paid-In Capital Chart

Hexima Annual Data

Trend

Jun08

Jun09

Jun10

Jun20

Jun21

Jun22

Jun23

Additional Paid-In Capital

Get a 7-Day Free Trial

Hexima Semi-Annual Data
	Dec06	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial										-	-	-	-	-

Hexima Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Hexima Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Hexima's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Hexima (ASX:HXL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.hexima.com.au

Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.